Encore Opportunities 2025: Cash Collection Finally Arrived, Now Capital Allocation Is on Trial

Getting to Know the Company

Encore Opportunities is not just a small, scattered story with a few unrelated assets. It is a foreign bond issuer sitting above a US operating group, and in practice its economics still depend mainly on two engines: SEC in emergency care and P4D in dental services. 2025 was the year when the first engine stopped looking like an aggressive accounting model and started looking like a real collection machine. That is the center of the story.

The positive side is obvious. Consolidated revenue rose to $376.8 million from $214.0 million in 2024. Operating profit climbed to $168.4 million from $39.9 million, net income reached $137.1 million, and cash flow from operations jumped to $154.2 million. Even revenue quality looks cleaner than before: cash collections from the emergency rooms and dental clinics were $380.6 million, while the financial statements recognized $372.9 million from those activities. In other words, the gap between what was reported and what actually came in is no longer a crater.

But anyone reading 2025 as “problem solved” is moving too fast. In emergency care there are still $900.2 million of open claims against only $33.4 million of revenue recognized from them. The revenue-recognition rate rose to 22.51% at the end of 2025 from 8.85% at the end of 2024, and that is a dramatic shift, but it still rests on collection trends and an arbitration system with insurers. At the same time, the company opened several new fronts in 2025, revenue-based financing, HUD-related financing, and convenience-store and travel-center assets, distributed $74 million to its shareholder, and after the balance-sheet date raised another NIS 210 million for M&A. That is why 2026 looks less like a victory lap and more like a capital-allocation test.

The framing also matters. In Israel this is a credit and capital-allocation story, not a liquid listed-equity story. There is no short-interest read, no live equity tape, and the group is financed through two bond series with different collateral packages over SEC and P4D. So the right question is not simply whether the two main businesses are good. It is how much of the new cash actually stays with the issuer, and how much is already pledged, distributed, or redirected into new verticals.

The Economic Map

What matters is that this map still does not tell the whole story. The convenience-store, travel-center, and HUD-related activities already require capital and management attention, but at this stage they barely carry weight in the income statement. So at the end of 2025 Encore is still first and foremost a healthcare company with add-ons, not yet a truly balanced multi-engine platform.

Events and Triggers

2025 was the year the debate moved from revenue-recognition quality to cash deployment. That shift did not happen in one headline event. It came through a sequence of triggers that moved both the numbers and the way they should be read.

Trigger one: SEC. This is the engine that changed the entire group’s economics. The revenue-recognition rate climbed from 8.85% at the end of 2024 to 22.51% at the end of 2025. At the same time, cash collections in the segment jumped to $264.4 million from $85.2 million in 2024. This did not come from a major increase in site count. It came mainly from changes in collection and arbitration mechanics with insurers. That is both the positive anchor and the central friction point in the whole thesis.

The chart shows why the annual total is not enough on its own. In the first three quarters of 2025 SEC collections were unusually strong. In the fourth quarter they slowed to $47.9 million, still far above $30.7 million in the fourth quarter of 2024, but below the pace of the earlier quarters. The slowdown was attributed to the holiday season and a US government shutdown that delayed claims processing. This is precisely what the market needs to retest in early 2026: was it just quarterly noise, or a reminder that the 2025 reset still depends on favorable operating conditions?

Trigger two: P4D. It did not produce the headline move, but it did provide continuity. Dental revenue rose to $117.4 million, operating profit to $20.0 million, and EBITDA to $28.7 million. At the same time collection days fell from 25 to 17, an 8-day improvement. That matters because it means this business is not only growing, but also releasing cash faster. During 2025 the company added six new clinics that are expected to generate about $2.1 million of annual EBITDA. This is not the heart of the thesis, but it is an important stabilizer inside it.

Trigger three: expansion outside the healthcare core. In 2025 the company built a small-business finance book with gross receivables of $42.2 million, or $40.6 million net after a $1.6 million expected-credit-loss allowance. At the same time, equity-accounted investments already reached $48.7 million, mainly tied to convenience stores and travel centers. These moves could diversify the profile over time, but at this stage they raise the execution bar well before they add material weight to the income statement.

Trigger four: the allocation test. In January 2026 Midroog reaffirmed a Baa1.il stable rating for another Series C expansion of up to NIS 210 million, explicitly earmarked for M&A. The rating did not receive any uplift from the collateral, because Midroog did not view the collateral quality as high enough. That is an important outside signal: even after 2025, the credit market is willing to recognize the improvement, but not willing to grant the company a free pass on the back of the pledges alone.

Efficiency, Profitability, and Competition

The central story of 2025 is not just growth. It is a change in the composition of profit. Anyone looking only at the top line misses that most of the jump came from one segment, and only then flowed through to the consolidated numbers.

SEC: Same platform, completely different arithmetic

SEC finished 2025 with revenue of $255.5 million, versus $112.5 million in 2024. Operating profit jumped to $146.8 million from $28.7 million, and EBITDA to $153.7 million from $35.7 million. This is not a routine improvement. It is the kind of change that rewrites the group’s math.

But the mechanism matters. SEC operates out of network, which means more pricing flexibility, but also a longer, more complex, and more volatile collection path. To address that, the company had already switched collection providers in 2023 and then brought in a specialist arbitration collections agent. During 2025 arbitration itself was also moved to QMACS at a lower cost structure. According to the company, collections through arbitration increased total insurance collections by a factor of 3. That is not a side note. It is the reason the year looks different.

The stronger point is that the improvement no longer sits only inside an estimate. In 2025 the company recognized $16.37 million of revenue from claims won in arbitration but not yet collected, and by February 3, 2026 it had already collected about $13 million of that amount. In other words, part of what still looked like a year-end accounting item had already started turning into cash shortly after the balance sheet date. That supports the direction of travel.

The less comfortable side is cost and sensitivity. Arbitration collections cost more than ordinary collections, 20% versus 5%. And at the end of 2025 there were still $900.2 million of open claims, of which $714.6 million were in appeal or arbitration. That stockpile is large enough to show how much SEC still depends on a complex regulatory and operational framework. It is no coincidence that the auditors flagged emergency-care revenue recognition as a key audit matter.

P4D: Less drama, more repeatability

P4D is not producing the same headline acceleration as SEC, but it is providing the more repeatable and more legible layer of the group. Revenue rose to $117.4 million from $101.5 million, operating profit to $20.0 million from $12.3 million, and EBITDA to $28.7 million from $19.3 million. Put simply, this is not an accounting surprise. It is steady operational improvement.

The part readers can easily miss is that this segment matters more because the environment around it is not easy. Midroog’s November 2025 review described a DSO market that is becoming more cautious, reassessing acquisition pace, and redirecting more capital toward improving existing clinics. Against that backdrop, P4D’s ability to keep growing while also reducing collection days is a real strength. It means this is not just a pledged asset supporting one bond series. It is a stabilizing earnings layer inside a group that has become much more dynamic elsewhere.

The new businesses have not yet proved that the extra complexity is worth it

In revenue-based finance the company already booked $3.7 million of revenue and $1.9 million of operating profit, but the real story is still on the balance sheet. Gross short-term customer credit stood at $42.2 million, with a total allowance of $1.6 million, including a $1.0 million specific allowance. That does not yet look like a problem, but it also does not look like a business that has completed a full cycle and proved its underwriting resilience.

That is where growth and diversification stop being the same thing. At the end of 2025 the new activities were still too small to reshape the operating thesis, but large enough to demand capital, management attention, and execution discipline. If underwriting in finance proves weaker than it looks today, or if the new assets need more capital than they return, the gap between “diversification” and “overextension” could close quickly.

Cash Flow, Debt, and Capital Structure

I am using an all-in cash-flexibility frame here, not a normalized one. The question is how much cash remained after the company’s actual uses of cash, investments, financing, distributions, repayments, and other real outflows, not how much the business might have generated before management decisions.

On that basis the picture is strong. Cash flow from operations was $154.2 million. Investing cash flow was negative $68.7 million, mainly due to investments in convenience stores and travel centers. Financing cash flow was negative $31.4 million. Within financing, the company issued about $94 million of bonds, repaid about $30 million of bonds, and distributed $86.3 million to owners and non-controlling interests. Even so, cash and cash equivalents ended the year at $74.9 million, up from $20.9 million at the start of the year.

This chart is the screening heart of the case. In 2025 Encore no longer looks like a company telling an EBITDA story without the cash to support it. It showed that it can generate cash even after real-world uses. At the same time, the same chart sharpens the next question: if the cash is now there, why was such a large amount distributed to the shareholder while the company was also opening new verticals and expanding debt?

The debt structure: less immediate pressure, more importance on allocation quality

At the end of 2025 the company had no bank loans, and its debt carries fixed rates. Current bond maturities stood at $8.2 million, and long-term bonds at $179.2 million. In the contractual maturity analysis, future bond payments totaled $251.9 million, including $25.9 million within one year, $25.1 million in years one to two, $31.5 million in years two to three, and $98.2 million in years three to four.

The complication here is not just the debt level. It is the structure. Series B is backed by P4D. Series C is backed by SEC. Each has first-priority pledges over the relevant segment shares and the cash flows generated by that segment. Economically, this does not erase the value of diversification. But it does mean the two main engines are not one fully fungible cash pool.

Midroog reinforced that point in January 2026. The rating remained Baa1.il with a stable outlook, but the collateral did not receive structural uplift. Put differently, even after 2025, the credit market is prepared to recognize the improvement, but not to treat the collateral package as a substitute for disciplined credit behavior.

What really belongs to the issuer

There is also a meaningful currency layer. The operations are dollar-based, but the bonds are shekel-denominated. At the end of 2025 bonds net of related interest payable amounted to $195.2 million, while cash and restricted cash denominated in shekels amounted to only $2.8 million. The result was a net currency expense of $15.9 million in 2025. A 2.5% move in the dollar-shekel exchange rate changes total comprehensive income by about $4.8 million. This is not a thesis-breaker, but it does mean not every operating improvement survives intact all the way to the bottom line.

Outlook and What Comes Next

Before looking forward, it is worth stopping on a few less obvious findings:

• The key test has already shifted from revenue recognition to collection durability. In 2025 Encore showed that collections can rise sharply, but the fourth quarter also showed that the pace can cool meaningfully.
• P4D matters more than it looks at first glance. It is not the segment generating the headline, but it is the one that reduces dependence on every SEC quarter looking like the second or third quarter of 2025.
• The new activities are still too small to change the thesis, but already large enough to change the risk profile. This is where credit investors start asking harder questions.
• After the January 2026 raise, the market will no longer be satisfied with proof that the company has cash. It will want proof that the new cash is not being used to increase risk faster than it increases return.

That is why 2026 looks like a proof year for capital allocation. Not a survival year. Not a reset year. And not yet a clean breakout year either. The company already proved in 2025 that it can generate cash. Now it has to prove three different things: that SEC collections remain strong even after a softer quarter, that the new businesses do not inject unwanted volatility, and that the balance between shareholder distributions, new debt, and new investments remains disciplined.

The good news is that there is real balance-sheet room to attempt this. Year-end cash was $74.9 million, equity reached $158.2 million, and the balance sheet no longer looks tight. The less good news is that the company chose at the same time to distribute $74 million to the shareholder, invest in new businesses, and keep raising debt. So every upcoming report will be judged not only by earnings, but by the quality of cash deployment.

From a near-term market-reading perspective, there are two opposing directions. Credit investors like stronger cash flow, a higher rating, and a larger cash position. But they also tend to become more suspicious when the same improvement arrives alongside rapid diversification, large distributions, and debt raises earmarked for M&A. So the next checkpoint is not only whether 2025 was a strong year. It is whether 2026 begins with the same operating discipline that created the 2025 reset.

Risks

The revenue-recognition model still rests on estimates, not on a fixed tariff card

Despite the improvement, SEC still operates in a world where the treatment price is not fixed up front with the payer, but is settled through negotiation, appeal, and arbitration. That creates upside, but also volatility. At the end of 2025 there were $900.2 million of open claims, and only $33.4 million of revenue recognized from them. Even if the direction is better, that gap is large enough to remind readers that the segment still depends on a collection infrastructure that can change for regulatory, legal, or operational reasons.

Rapid expansion into new verticals can improve the profile, but it can also dilute focus

Midroog stated the point almost explicitly: investments in convenience stores, small-business finance, and HUD-related financing raise credit risk until they build a longer track record. That is the right criticism. As of the end of 2025 the new activities were not yet producing enough operating mass to justify all the additional complexity. If underwriting in the finance business proves weaker than it looks, or if the new assets demand more capital than expected, the line between diversification and overreach will narrow quickly.

Shekel debt over a dollar business is not a technical footnote

The $15.9 million net currency expense in 2025 is not noise. It is a reminder that even a company showing strong operational improvement can still absorb a real financial hit because of a currency mismatch. Since the debt is in shekels and the earnings engine is in dollars, exchange-rate volatility will remain part of the picture.

This is a foreign issuer, and that is a real structural credit risk

The company is incorporated in the British Virgin Islands, operates in the US, and has bonds in Israel. In an extreme insolvency scenario, the process could be pulled across several legal jurisdictions. That is not the central thesis today, but for bondholders it remains a meaningful structural yellow flag, especially because there is no listed public-equity layer here to absorb stress before the debt does.

Conclusions

2025 was the year Encore moved from defense to offense. SEC repaired the collection mechanism and transformed the consolidated picture, P4D kept improving collection quality and provided a steadier profit layer, and the year-end cash balance finally looks like the cash balance of a company that knows how to generate real money. But this is also exactly the point where the harder test begins: will management use that cash to deepen an engine that already proved itself, or to build too many new theses too quickly?

Current thesis: Encore has solved a large part of its historical cash problem, but 2026 will be judged mainly on capital-allocation discipline rather than on the ability to generate EBITDA.

What changed: The gap between collections and reporting narrowed materially, SEC moved from being the main source of skepticism to being the main source of improvement, and the group entered 2026 with far more liquidity confidence.

Counter-thesis: 2025 may prove to have relied too heavily on an unusually favorable SEC collection window, and if that cools while the company is already expanding into new businesses and adding debt, the year’s earnings base may not repeat.

What could change the market reading: Two things. Continued strong SEC collections even after the fourth-quarter slowdown, and proof that the January 2026 proceeds are being deployed into disciplined transactions rather than just broader risk appetite.

Why this matters: Because Encore is no longer being judged on whether it can rescue the accounting story. It is being judged on whether it can turn a sharp operational improvement into a stronger capital structure and responsible growth.

Over the next 2 to 4 quarters Encore needs to prove three things: that SEC collection momentum does not roll back, that the new businesses do not produce underwriting surprises or excessive capital drag, and that after the January 2026 raise management operates with tighter discipline than it showed in the 2025 distributions. If all three happen together, 2025 will look like a new base. If not, it may end up looking like a very strong year that arrived right before a broader risk expansion.